tbuckley/cabot-search huggingface dataset:
SAT0611 The Impact of Adherence To Biologic Agents on Health Care Resource Utilization for Patients with Rheumatoid Arthritis
Authors: U. Lathia, F. Nantel, E. Ewara
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Poor adherence to therapy increases the burden and complexity of chronic diseases such as rheumatoid arthritis (RA). In the past 15 years, biologics have revolutionized the treatment of RA. However, little data is available on impact of adherence to biologics on health-care resources. <h3>Methods</h3> As part of a pilot project at the Institute for Clinical Evaluative Sciences (ICES), analyses were performed by ICES scientists on ICES administrative data to study the research question provided by Janssen Inc. Note, the approach and methodological details were determined by Janssen researchers. Patients were identified from the Ontario RA Database which contains all Ontario RA patients identified since 1991. Study population included RA patients, age 65+, with a prescription for a biologic drug between January 1, 2003 and December 31, 2013. Exclusion criteria are diagnosis of inflammatory bowel disease, psoriatic arthritis or psoriasis in the 5 years prior to the index event and discontinuation of biologic drug during the 12 months after the index event. Adherence was defined as a Medication Possession Ratio (MPR) of ≥0.8 measured as the proportion of days for which a patient had biologic treatment(s) over a defined follow-up period. Adherent were matched to non-adherent patients on a propensity score calculated using seventeen variables capturing patient demographics and heathcare resource use in the year prior to index event. <h3>Results</h3> A total of 4,667 RA patients were identified. Patients had a mean age (SD) of 69.9 (5.46) years and 75% were female. Of the total study cohort 1,877 matched pairs were identified (adherent to non-adherent patients). Relative rates for resource use (GP and cardiologist visits, ED visits, hospitalization, home care and rehabilitation) for the matched cohort were significantly lower (p&lt;0.0001) in adherent patients. Additionaly the median (IQR) length of stay of hospitilizations was shorter for adherent patients - 10 days (4–23) vs. 14 days (5–38). 67% of non-adherent patients used oral prednisone which is significantly higher (p&lt;0.001) than 54% in the adherent cohort. <h3>Conclusions</h3> The results of this large population based study have shown that RA patients who are adherent to biologic therapy have lower heathcare resource use and lower steroid use compared to non-adherent patients. Despite the inherent limitations of administrative database studies, the findings of the study have implications for physicians, patients and healthcare payers demonstarting the importance of adherence in the management of RA. <h3>Disclosure of Interest</h3> None declared
Oral Mucositis Incidence and Severity after Methotrexate and Non-Methotrexate Containing GVHD Prophylaxis Regimens.
Authors: Corey Cutler, Shuli Li, Haesook T. Kim, Patricia Laglenne, Colleen Ford, Vincent Ho, Stephanie J. Lee, Edwin Alyea, Robert Soiffer, Joseph H. Antin, Stephen Sonis
Journal: Blood (2004)
THU0405 Ability of General Practitioners To Distinguish between Inflammatory and Non-Inflammatory Symptoms in Patients at Risk of Spondyloarthritis: The AppSpA Study
Authors: M.C. Karreman, J.M. Hazes, A.E. Weel
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Over the last couple of years early arthritis clinics provided quick access for patients with inflammatory arthritis. However, although early access to specialized care is now available, adequate referrals are also required to shorten the doctors9 delay. Therefore, general practitioners (GPs), the ones who refer, should be aware of symptoms distinguishing between inflammatory and non-inflammatory disease in patients at risk for spondyloarthritis (SpA). <h3>Objectives</h3> To describe GP9s ability to recognize symptoms suggestive of spondyloarthritis. <h3>Methods</h3> The AppSpA study was set up, a cross-sectional study focusing on awareness and knowledge of SpA in GPs and patients at risk for SpA. For the present study a single survey was developed and send out to GPs in various regions of the Netherlands. This survey was based on a study by Jois et al, which looked into recognition of symptoms of inflammatory back pain. Since we were also interested in the ability of GPs to recognize peripheral manifestations of SpA, we added some extra questions. <h3>Results</h3> 183 of the 950 GPs completed the survey, leading to a participation rate of 19.3%. Of the participating GPs the mean age was 47.2 years (SD 10.3) and 47.5% were male. Mean time working as a GP was 15.4 years (SD 13.5). Almost all GPs (94.5%) indicated to be familiar with the term SpA, but 55.5% associated it only with axial manifestations. Up to one third of the GPs associated the term SpA with psoriatic arthritis (23.7%) and Inflammatory Bowel Disease (33.5%). With regard to the recognition of signs of inflammatory pain, especially morning stiffness and pain relieve by NSAIDs were recognized (Table 1), whereas pain improvement with exercise was recognized in less than 25% of cases. When we focus on the peripheral manifestations of SpA; out of six signs for inflammatory peripheral disease, only 43.2% of GPs recognized at least three of these symptoms. For the eight axial signs, 60.6% recognized at least four symptoms. If GPs thought about inflammatory symptoms, the majority asked for the presence of psoriasis (83.6%) and inflammatory bowel disease (72.1%). GPs less often ask about other SpA related symptoms such as uveitis (61.8%), enthesitis (19.1%) and dactylitis (19.1%). <h3>Conclusions</h3> Overall, recognition of inflammatory disease by GPs is suboptimal, where GPs are more aware of axial manifestations compared to peripheral manifestations. The recognition of these signs and symptoms of SpA in primary care needs improvement in order to facilitate the necessary referrals to rheumatologists. <h3>Acknowledgement</h3> This survey is part of initiative to develop a communication platform which was financially supported by AbbVie. <h3>Disclosure of Interest</h3> None declared
PTH-003 Prone or Left Starting Position for Colonoscopy? A Randomised Controlled Trial
Authors: AJ Scarborough, JA Morris, N Vergis, J Hoare
Journal: Gut (2016)

<h3>Introduction</h3> Colonoscopy is an essential modality in gastroenterology but can be technically challenging and cause patient discomfort. By convention, the procedure is started with patients in the left lateral position. The recent ROLCOL study has shown that right lateral starting position may be preferable to left lateral starting position. However, a prone starting position for colonoscopy has not been tested with the same rigour. One study found that obese patients undergo quicker procedures when colonoscopy is started with the patient in the prone position. We sought to test the benefits of prone positioning over conventional left lateral positioning in unselected patients. <h3>Methods</h3> 181 consecutive patients undergoing scheduled colonoscopy were stratified according to age, gender, BMI and experience of the endoscopist. Patients were then randomised to begin colonoscopy in either the prone (PP) or left lateral (LP) position. The primary outcome measure was time to reach cecum. Secondary outcome measures included: <i>i) </i>time to reach transverse colon; <i>ii) </i>patient comfort and <i>iii) </i>endoscopist’s perception of procedure difficulty, both assessed by visual analogue scale (VAS). <h3>Results</h3> Time to reach cecum was longer for patients randomised to start colonoscopy in the PP compared to the LP (700 s vs. 525 s; p &lt; 0.05). This was in line with a longer time to reach the transverse colon in the PP group (329 s vs. 257 seconds; p &lt; 0.05) as well as an increase in the difficulty perceived by the endoscopist for procedures in which the patient was positioned prone (5 vs. 4 VAS; p &lt; 0.01). The doses of intravenous sedation used (midazolam 2 vs 2 mg; p = 0.27 and fentanyl 50 vs 50 mcg; p = 0.68) and patient comfort scores (3.5 vs. 4 VAS, p = 0.43) were similar between the two groups. In subgroup analysis, a statistically significant increase in time to cecum was shown in particular for female patients positioned prone at the start of colonoscopy (771.5 s vs. 522.5 s, p &lt; 0.01). <h3>Conclusion</h3> Starting patients in the prone position led to an increased cecal intubation time and was more technically challenging for the endoscopist. Our results do not, therefore, support the prone position as the optimal starting position for colonoscopy in unselected patients. Future research should focus on elucidating the situations in which position change to prone during colonoscopy is helpful. <h3>Disclosure of Interest</h3> None Declared
AB0093 Regulation of Autophagic Flux Alters Interleukin-17A-Induced Migration and Proliferation of Fibroblast-like Synoviocytes from The Patients with Rheumatoid Arthritis
Authors: J.-M. Kim, J. Bang, Y.S. Kim, H.-S. Kim, S.-J. Hong, S.-S. Kim, H.-J. Jeong, C.-N. Son, S.-H. Kim
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Interleukin-17A (IL-17A) plays a critical role in the pathogenesis of rheumatoid arthritis (RA), which is characterized by exaggerated synovial proliferation. Autophagy is required to prevent accumulation of cellular damage and to ensure cellular homeostasis. Dysregulated autophagy has been reported to be involved in the pathogenesis of several diseases such as cancer and infections. Here, we hypothesized that IL-17A, a key cytokine in the development of RA, might have an impact on autophagic flux and that aberrant autophagy might be involved in expansion of synovial fibroblasts in the patients with RA, which is stimulated by pro-inflammatory cytokines. <h3>Objectives</h3> The aims of this study were (1) to evaluate whether IL-17A influences on autophagic flux in the synovium of the patients with RA and (2) to investigate whether the modulation of autophagy can regulate migration and proliferation of fibroblast-like synoviocytes (FLS) from the patients with RA (RA-FLS) under inflammatory milieu. <h3>Methods</h3> Synovial tissue was obtained from the patients with RA or osteoarthritis (OA) during total knee replacement surgery. FLS was cultured with IL-17A, autophagy inducer or inhibitor. The expression of marker proteins for autophagic flux (LC3B, Beclin1, Atg5, p62) and the formation of autophagolysosome (LAMP1) were analyzed by western blot. A migration scratch assay was used to assess FLS migration in response to stimulation with IL-17A. Proliferation of FLS was determined by the viable cell count using trypan blue. Bafilomycin was used for inhibiting autophagic flux. <h3>Results</h3> The expression of autophagy markers (LC3B, Beclin1, Atg5) was increased in the synovium of the patients with RA than in that of the patients with OA. Autophagy was also enhanced in RA-FLS compared with OA-FLS. IL-17A upregulated the expression of LC3B, Atg5, Beclin1, LAMP1 in RA-FLS. In particular, IL-17A-induced accumulation of p62 was prominent in RA-FLS. Migration and proliferation of FLS stimulated by IL-17A was suppressed by the inhibition of autophagy. <h3>Conclusions</h3> This study reveals that IL-17A stimulates autophagic flux and that intervention of autophagy can control IL-17A-induced migration and proliferation of FLS. Our results also provide additional evidence for a significant role of autophagy in the pathogenesis of RA. Thus, we suggest that autophagy might be a potential therapeutic target for the management of RA. <h3>References</h3> Lin NY, Beyer C, Giessl A, et al. Autophagy regulates TNFα-mediated joint destruction in experimental arthritis. Ann Rheum Dis. 2013 May;72(5):761–8. Connor AM, Mahomed N, Gandhi R, et al. TNFα modulates protein degradation pathways in rheumatoid arthritis synovial fibroblasts. Arthritis Res Ther. 2012 Mar 14;14(2):R62. <h3>Disclosure of Interest</h3> None declared
Abstract 170: Chest Compression Performance Evaluation: Introduction and Utilization of the Quality Compression Index in a Manikin Model
Authors: John Schwab, Todd Cole, Josh Erdman, Susan Olson, Zachary T Emberts, Andrea Williams, Patricia Padjen, Marvin Birnbaum
Journal: Circulation (2010)

Purpose: Both standard cardiopulmonary resuscitation (CPR) and continuous chest-compression CPR require rescuers to push hard and fast. In practice, both techniques require the optimal delivery of chest compressions. However, the performance of chest compressions and the degree by which fatigue affects performance has not been well-documented in a larger, older, and more diversified sample. It was hypothesized that rescuer fatigue would lead to decreased performance after the first two minutes, which is the current recommended time to switch compressors. Methods: In this observational study, basic life support (BLS)-certified healthcare providers were evaluated based on their ability to provide 10 minutes of continuous chest compressions. Compression depth, rate, chest recoil, and hand position were recorded in 30 second intervals using the Laerdal PC Skillreporting System. Adequate compressions were recorded as having adequate depth (>38 mm), correct hand position, and complete recoil. Investigators deve...
Comparable Survival in Newly Diagnosed Multiple Myeloma (MM) after VAD Induction with High Dose Therapy Using Melphalan 140mg/M2 + TBI 12 Gy (MEL+TBI) Versus Standard Therapy with VBMCP and No Benefit from Interferon (IFN) Maintenance: Final Clinical Results of Intergroup Trial S9321 in the Context of IFM 90 and MRC VII Trials.
Authors: John Crowley, Rafael Fonseca, Phillip Greipp, McCoy Jason, Barlogie Bart
Journal: Blood (2004)
Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome–Diarrhea Without Bile Acid Malabsorption
Authors: Cédric Peleman, Michael Camilleri, Irene Busciglio, Duane Burton, Leslie Donato, Alan R. Zinsmeister
Journal: Clinical Gastroenterology and Hepatology (2016)
Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration
Authors: Rebecka L Meyers, Rudolf Maibach, Eiso Hiyama, Beate Häberle, Mark Krailo, Arun Rangaswami, Daniel C Aronson, Marcio H Malogolowkin, Giorgio Perilongo, Dietrich von Schweinitz, Marc Ansari, Dolores Lopez-Terrada, Yukichi Tanaka, Rita Alaggio, Ivo Leuschner, Tomoro Hishiki, Irene Schmid, Kenichiro Watanabe, Kenichi Yoshimura, Yurong Feng, Eugenia Rinaldi, Davide Saraceno, Marisa Derosa, Piotr Czauderna
Journal: The Lancet Oncology (2016)
In Vitro and in Vivo Single-Agent Efficacy of Checkpoint Kinase 1 (Chk1) and 2 (Chk2) Inhibitor PF-0477736 (Pfizer) in B- and T-Acute Lymphoblastic Leukemia (ALL)
Authors: Ilaria Iacobucci, Andrea Ghelli Luserna Di Rorà, Maria Vittoria Verga Falzacappa, Enrico Derenzini, Anna Ferrari, Cristina Papayannidis, Claudia Venturi, Annalisa Lonetti, Viviana Guadagnuolo, Federica Cattina, Emanuela Ottaviani, Maria Chiara Abbenante, Domenico Russo, Michele Baccarani, Pier Giuseppe Pelicci, Giovanni Martinelli
Journal: Blood (2012)
Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease
Authors: Amit V. Khera, Connor A. Emdin, Isabel Drake, Pradeep Natarajan, Alexander G. Bick, Nancy R. Cook, Daniel I. Chasman, Usman Baber, Roxana Mehran, Daniel J. Rader, Valentin Fuster, Eric Boerwinkle, Olle Melander, Marju Orho-Melander, Paul M Ridker, Sekar Kathiresan
Journal: New England Journal of Medicine (2016)

Both genetic and lifestyle factors contribute to individual-level risk of coronary artery disease. The extent to which increased genetic risk can be offset by a healthy lifestyle is unknown.
Reduced Production of Mature Neutrophils From Induced Pluripotent Stem Cells Derived From a Severe Congenital Neutropenia Patient with HAX1 Gene Deficiency
Authors: Tatsuya Morishima, Ken-ichiro Watanabe, Akira Niwa, Takayuki Tanaka, Katsutsugu Umeda, Hidefumi Hiramatsu, Kousaku Matsubara, Souichi Adachi, Tatsutoshi Nakahata, Toshio Heike
Journal: Blood (2011)
AB0602 Increased Stiffness of Median Nerve in Systemic Sclerosis:
Authors: I. Yagci, O. Kenis Coskun, T. Ozsoy, G. Ozen, H. Direskeneli
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The frequency of peripheral nerve involvement has been debated in systemic sclerosis (SS). Despite the patients have clinical symptoms such as numbness and paresthesia the electrodiagnostically proven neuropathy incidence is low. <h3>Objectives</h3> The aims of this study are to document peripheral neuropathies in a cohort of SS and compare the sonoelastrographic measurements of median nerves in systemic sclerosis, idiopathic carpal tunnel syndrome and healthy controls. <h3>Methods</h3> The clinical, electrophsiological and ultrasonographic assessments were done by three masked researchers. Patients with SS and CTS were assessed with nerve conduction studies. The sonoelastography and sonographic assessments of the median nerve were perfomed with 6–18 Mhz lineer transducer. The measurements of cross sectional areas (CSA)were performed at psiform and forearm level from axial US images. The sonoelastrography was performed with same transducer and same sonographer. The median nerve was visualized in axial view and kept in center of the screen. Seven-10 slight compressions were made periodically by the sonographer until the device determined that the proper elastographic view was obtained. The elastic ratio is the ratio of strain distribution in two selected region of interests (ROI). A round ROI was positioned in the center median nerve, while a same size of ROI was positioned in a homogeneously soft anatomical structure, which was considered as internal control. Second ROI was positioned on the flexor carpi radialis for the wrist level and flexor digitorum superficialis for the forearm level. The ROIs were fixed to 2 mm. By using this method, a higher elastic ratio reflects a lower elasticity of median nerve. <h3>Results</h3> The study was completed with 47 hands of 24 patients with SS, 53 hands of patients with CTS and 38 hands of health controls. According to electrodiagnostic testing 17 patients were normal, 4 patients were diagnosed as CTS and 3 patients were diagnosed as polyneuropathy in patients with SS. The CSA of CTS group was significantly higher than systemic sclerosis and control groups. The elastic ratio at psiform level and forearm levels of systemic sclerosis group were significantly higher than the CTS and control groups. There was no statistical difference between CTS and control groups. <h3>Conclusions</h3> The frequency of peripheral neuropathy is increased in SS. The median nerves loose the elasticity in both wrist and forearm level where the CSA9s are in the normal range. These results suggested that the increased peripheral nerve involvement in SS is about the increased stiffness of the nerves. <h3>Disclosure of Interest</h3> None declared
Polyhedrocytes: Compressed Polyhedral Erythrocytes In Contracted Blood Clots and Thrombi
Authors: John W. Weisel, Tatiana Lebedeva, Chandrasekaran Nagaswami, Vincent M. Hayes, Walter Massefski, Rustem I. Litvinov, Lubica Rauova, Thomas J. Lowery, Douglas B. Cines
Journal: Blood (2013)
Reducing Adverse Drug Events
Authors: Chad Kessler, Michael J. Ward, Candace D. McNaughton
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Phase I/II Study of Lenalidomide, Intermediate Dose Dexamethasone and Low Dose Cyclophosphamide (RDC) for the Treatment of Patients with Primary Systemic Amyloidosis (AL).
Authors: Efstathios Kastritis, Flora Zagouri, Maria Roussou, Magdalini Migkou, John Boletis, Theofanis Apostolou, Meletios A. Dimopoulos
Journal: Blood (2008)
The Unexpected Role of C3a-C3aR Axis in Maturation of Erythroid Cells - Implications for Pathogenesis of Hypoxia-Related Polycythemias.
Authors: Janina Ratajczak, Ryan Reca, Bogdan Machalinski, Jaroslaw Maciejewski, Mary Laughlin, Mariusz Z. Ratajczak
Journal: Blood (2006)
Modeling JAK2V617F Heterozygous and Homozygous Mutations by Using Induced Pluripotent Stem Cells Derived From Myeloproliferative Neoplasms Patients
Authors: Joseph Saliba, Sofiane Hamidi, Antonio Di Stefano, Thierry Langlois, Gaëlle Lenglet, Lise Secardin, Anne Galy, Paule Opolon, Najet Debili, Hana Raslova, Françoise Norol, Isabelle Plo, William Vainchenker
Journal: Blood (2012)
A Pilot Study Comparing Megestrol Acetate Concentrated Suspension (MA-CS) to Megestrol Acetate Oral Suspension (MA-OS) on Weight Gain and Body Composition in Patients with HIV-Associated Unintended Weight Loss (UWL).
Authors: Donald D. Cilla, Jodi L. Gutierrez, Robert A. Femia, Lynn D. Kramer, Christine Wanke
Journal: Blood (2005)
Incidence of Venothromboembolism (VTE) in Patients (pts) with Acute Lymphocytic Leukemia (ALL), Burkitt’s Leukemia/Lymphoma (BL) or Lymphoblastic Leukemia (LL).
Authors: Khanh D. Vu, Deborah A. Thomas, Julie C. Hubbard, Stefan Faderl, Jorge Cortes, Maria E. Cabanillas, Guillermo Garcia-Manero, Susan M. O’Brien, Hagop Kantarjian
Journal: Blood (2006)
Progress and Paradigms in Multiple Myeloma
Authors: Kenneth C. Anderson
Journal: Clinical Cancer Research (2016)

Abstract Remarkable progress has been achieved in multiple myeloma, and patient median survival has been extended 3- to 4-fold. Specifically, there have been 18 newly approved treatments for multiple myeloma in the past 12 years, including seven in 2015, and the treatment paradigm and patient outcome have been transformed. The definition of patients benefitting from these therapies has been broadened. Response criteria now include minimal residual disease (MRD), assessed in bone marrow by multicolor flow cytometry or sequencing, and by imaging for extramedullary disease. Initial therapy for transplant candidates is a triplet incorporating novel therapies—that is, lenalidomide, bortezomib, and dexamethasone or cyclophosphamide, bortezomib, and dexamethasone. Lenalidomide maintenance until progression can prolong progression-free and overall survival in standard-risk multiple myeloma, with incorporation of proteasome inhibitor for high-risk disease. Studies are evaluating the value of early versus late transplant and MRD as a therapeutic goal to inform therapy. In nontransplant patients, triplet therapies are also preferred, with doublet therapy reserved for frail patients, and maintenance as described above. The availability of second-generation proteasome inhibitors (carfilzomib and ixazomib), immunomodulatory drugs (pomalidomide), histone deacetylase inhibitors (panobinostat), and monoclonal antibodies (elotuzumab and daratumumab) allows for effective combination therapies of relapsed disease as well. Finally, novel therapies targeting protein degradation, restoring autologous memory anti–multiple myeloma immunity, and exploiting genetic vulnerabilities show promise to improve patient outcome even further. Clin Cancer Res; 22(22); 5419–27. ©2016 AACR. See all articles in this CCR Focus section, “Multiple Myeloma: Multiplying Therapies.”